Lavage With Super-Oxidized Solution for Secondary Peritonitis
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Sep 9, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for a serious abdominal condition called secondary peritonitis, which can occur after issues like a perforated organ or an infection. The researchers want to find out if washing the abdominal cavity with a special solution, known as super-oxidized solution (SOS), can help reduce the risk of infections and death in patients undergoing emergency surgery for this condition. The hope is that using this solution will lead to better outcomes for patients facing this medical emergency.
To participate in the trial, individuals must be over 18 years old and scheduled for emergency abdominal surgery due to secondary peritonitis. They should not be pregnant or have certain types of peritonitis that are not the focus of this study. Participants can expect to receive careful monitoring during and after their treatment. By joining this trial, they have the chance to contribute to important research that could improve care for future patients with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Secondary peritonitis due to suspected hollow viscus perforation, anastomotic insufficiency, and/or abdominal abscess (including patients with the named abdominal emergencies as a complication after elective surgery)
- • Scheduled emergency abdominal surgery by laparotomy with peritoneal lavage
- • Age over 18 years
- • Written informed consent
- • Exclusion Criteria
- • Pregnancy (will be ruled out using beta-hCG testing in women of childbearing potential)
- • Patients with primary or tertiary peritonitis
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Tobias Haltmeier, MD
Principal Investigator
Inselspital, Bern University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials